Mirum Pharmaceuticals, Inc. , a leading rare disease company, today announced that Health Canada has authorized the tablet formulation of LIVMARLI® (maralixibat) for the treatment of cholestatic ...
As the management landscape of primary biliary cholangitis (PBC) changes, new second-line options offer effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results